Celator Pharmaceuticals Inc
Healthcare · Pharmaceutical Preparations · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY15 | FY14 | FY13 | FY12 | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | −$18.2M | −$17.9M | −$14.6M | −$8.0M |
| Net income | −$19.3M | −$16.9M | −$20.8M | −$10.9M |
| Total assets | $25.6M | $35.1M | $27.5M | $13.4M |
| Total liabilities | $19.1M | $13.2M | $4.0M | $6.6M |
| Equity | $6.5M | $21.9M | $23.5M | $6.9M |
| EPS (diluted) | — | — | — | — |
| Shares out. | 33.7M | 26.0M | 26.0M | 13.7M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2015- Operating margin
- —
- Net margin
- —
- Return on equity
- −295.8%
- Return on assets
- −75.3%
- Return on capital (ROCE)
- −106.7%
- Liabilities / assets
- 74.5%
- Debt / equity
- 2.93×
- Book value / share
- $0.19
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2015- Altman Z″ (distress)
- -21.84distress
- Accruals / assets
- −14.9%clean
- Piotroski F-Score
- 1/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 2 warning● 1 good- Altman Z″ in the distress zone
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Other material eventJul 12, 2016
- Other material eventJun 14, 2016
- Other material eventJun 6, 2016
- Entered a material agreement · Amended charter or bylaws · Other material eventMay 31, 2016
- Entered a material agreement · Director / officer changeApr 27, 2016
- Director / officer changeApr 5, 2016
- Entered a material agreement · Other material eventMar 23, 2016
- Results of operationsMar 21, 2016
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- CT ORDERFeb 13, 2018
- SC 13G/AFeb 15, 2017
- SC 13G/AQUAKER BIOVENTURES, L.P. SCHEDULE 13G/AFeb 14, 2017
- SC 13G/AJan 30, 2017
- 15-12B/AAug 2, 2016
- EFFECTAug 1, 2016
- POS AMPOST EFFECTIVE AMENDMENT NO. 1 TO FORM S-1Jul 27, 2016
- EFFECTJul 25, 2016
- 15-12BJul 22, 2016
- SC 13D/AJul 15, 2016
- 4PRIMARY DOCUMENTJul 13, 2016
- 4OWNERSHIP DOCUMENTJul 12, 2016
- 4OWNERSHIP DOCUMENTJul 12, 2016
- 4OWNERSHIP DOCUMENTJul 12, 2016
- 4PRIMARY DOCUMENTJul 12, 2016
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.